SCHEMBL29137729

SCHEMBL29137729

CC(C(=O)OC(C)(C)C)c1cnc(Cl)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.46
KMT2A Q03164 5/20 0.42
LMNA P02545 1/20 0.42
TRPA1 O75762 1/20 0.37
STK17B O94768 1/20 0.36
STK17A Q9UEE5 1/20 0.36
MAPT P10636 6/20 0.34
MAPK1 P28482 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
NPR3 P17342 1/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 3/20 0.33
ALDH1A1 P00352 3/20 0.33
RECQL P46063 1/20 0.33
P2RY2 P41231 1/20 0.32
B3GNT2 Q9NY97 1/20 0.32
GAA P10253 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29137732 0.81 PTGS1 (0.41) KMT2ALMNAMAPTMAPK1MEN1
SCHEMBL29254962 0.80 KMT2A (0.46) APPKMT2ALMNATRPA1STK17B
SCHEMBL27485847 0.79 APP (0.42) APPKMT2ALMNAMAPTNPSR1
SCHEMBL28520070 0.78 TRPA1 (0.45) KMT2ALMNATRPA1STK17BSTK17A
SCHEMBL27832415 0.76 FFAR2 (0.33) KMT2ALMNAMAPTMAPK1POLB
SCHEMBL6349692 0.76 APP (0.58) APPKMT2ALMNAMAPTMAPK1
SCHEMBL30768172 0.74 PTGS2 (0.42) APPKMT2ALMNAMAPTMAPK1
SCHEMBL20581073 0.74 TRPA1 (0.44) KMT2ALMNATRPA1STK17BSTK17A
SCHEMBL27946209 0.72 MAPK1 (0.42) APPKMT2ALMNATRPA1MAPT
SCHEMBL22645507 0.72 STK17B (0.40) KMT2ALMNATRPA1STK17BSTK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015352-A1 METHYLTRANSFERASE INHIBITOR AND USE THEREOF CYTOSINLAB THERAPEUTICS CO LTD (CN) 2026-01-15 US disclosed
CN-117384153-A Methyltransferase inhibitors and uses thereof 上海赛岚生物科技有限公司 2024-01-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015352-A1 METHYLTRANSFERASE INHIBITOR AND USE THEREOF EZH2, DOT1L, EHMT1 APP 4350/4885KMT2A 16/4885LMNA 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.